Skip to main content

A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma""

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

NanoCarrier Co., Ltd.

Start Date

May 19, 2017

End Date

September 30, 2022
 

Administered By

Duke Cancer Institute

Awarded By

NanoCarrier Co., Ltd.

Start Date

May 19, 2017

End Date

September 30, 2022